Fig. 2

BTK inhibitor ibrutinib suppresses the proliferation of glioma cells. (a) U87 and U251 cells were treated with the indicated concentration of ibrutinib for 72 h. The cell viability was measured using CCK-8 assays. (b) HA1800 and U87 cells were treated with the indicated concentration of ibrutinib for 72 h. The cell viability was measured using CCK-8 assays. (c-f) The Ibrutinib-induced inhibition of DNA synthesis was determined by EdU incorporation assays. The EdU incorporation rate was presented as the ratio of EdU positive cells to total DAPI positive cells